Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.35 |
| ▸ | QPCT | Q16769 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129502 | 0.88 | MAPT (0.41) | MAPTALDH1A1LMNAPDE4AADORA2A | |
| SCHEMBL5133382 | 0.85 | MAPT (0.43) | MAPTPOLBALDH1A1LMNAPDE4A | |
| SCHEMBL5131623 | 0.84 | QPCT (0.44) | ALDH1A1HTTLMNACYP1A2PDE4A | |
| SCHEMBL5133070 | 0.84 | PDE1A (0.35) | ALDH1A1LMNAADORA2BQPCTKMT2A | |
| SCHEMBL14945530 | 0.82 | GRIN2D (0.35) | MAPTPOLBALDH1A1LMNAADORA2B | |
| SCHEMBL14945533 | 0.81 | ALDH1A1 (0.34) | MAPTALDH1A1LMNAADORA2BQPCT | |
| SCHEMBL5132724 | 0.81 | ALDH1A1 (0.38) | ALDH1A1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL13206028 | 0.81 | ALDH1A1 (0.37) | MAPTPOLBALDH1A1HTTLMNA | |
| SCHEMBL7593499 | 0.81 | ALDH1A1 (0.42) | MAPTALDH1A1LMNACYP1A2HPGD | |
| SCHEMBL5133324 | 0.81 | POLB (0.36) | MAPTPOLBALDH1A1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776868-B2 | Substituted bicyclic and tricyclic thieno[2,3-d]pyrimidines as A2A adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776868-B2 | Substituted bicyclic and tricyclic thieno[2,3-d]pyrimidines as A2A adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1989210-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080188495-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188495-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2007103776-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208040-A1 | e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction | GILEAD PALO ALTO, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208040-A1 | e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction | GILEAD PALO ALTO, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208040-A1 | e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction | GILEAD PALO ALTO, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208040-A1 | e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction | CHRNE, CHRNA3, CHRNA1 | MAPT 403/4885POLB 1603/4885ALDH1A1 419/4885 |
| US-20080188495-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | MAPT 1008/4885POLB 2132/4885ALDH1A1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.